Biotechnology and business development veteran Sonia Gulati holds a PhD from Columbia University, where she received a number of honors, including the Marija Chouinard Award for Excellence in Research. Currently, Sonia Gulati serves as the executive- in-residence at Kairos Ventures in New York, where she works closely with scientists to execute commercialization plans for portfolio companies.
Since its founding in 2015, Kairos Ventures has nourished global scientific discoveries through an expert-driven investment and commercialization process. The firm focuses its efforts on startups and formative-stage companies. Currently, Kairos Ventures invests in over 80 entities that include:
*1200 Pharma - a pharmaceutical firm that accelerates preclinical discovery and clinical approval timelines by applying innovative medicinal chemistry technology.
*Behavioral Signals - a technology firm that develops human behavior analysis and emotion- tracking solutions.
*Xidas - a micro-device production firm that develops products for high-value business sectors like aerospace and medicine.
*nFugue - a developer of nano-architected materials for industries that include healthcare, textiles, and aerospace.
For a complete list of the companies in Kairos Ventures’ portfolio, visit www.kairosventures.com.
